Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment

Journal of Clinical Oncology

Volumn 27, Issue 33, 2009, Pages 5660-5669

  Philip, Philip A ^a   Mooney, Margaret ^a   Jaffe, Deborah ^a   Eckhardt, Gail ^a   Moore, Malcolm ^a   Meropol, Neal ^a   Emens, Leisha ^a   O'Reilly, Eileen ^a   Korc, Murray ^a   Ellis, Lee ^a   Benedetti, Jacqueline ^a   Rothenberg, Mace ^a   Willett, Christopher ^a   Tempero, Margaret ^a   Lowy, Andrew ^a   Abbruzzese, James ^a   Simeone, Diane ^a   Hingorani, Sunil ^a   Berlin, Jordan ^a   Tepper, Joel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CANCER VACCINE; CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUOROURACIL; GEMCITABINE; IXABEPILONE; K RAS PROTEIN; OXALIPLATIN; PACLITAXEL; PROTEIN KINASE; RAC PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STEM CELL; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; METASTASIS; METHODOLOGY; MOLECULAR BIOLOGY; NATIONAL HEALTH ORGANIZATION; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL RATE; TRANSGENIC MOUSE; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; CANCER INVASION; CANCER STAGING; CONSENSUS DEVELOPMENT; DISEASE FREE SURVIVAL; DISEASE MODEL; DRUG DELIVERY SYSTEM; FEMALE; MALE; MORTALITY; MOUSE; MULTIMODALITY CANCER THERAPY; PANCREAS CARCINOMA; PANCREAS RESECTION; PANCREAS TUMOR; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; UNITED STATES;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MICE; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; UNITED STATES;

EID: 73949107880     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.9022     Document Type: Conference Paper

References (61)

1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
3. Rothenberg M, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FUrefractory pancreas cancer. Ann Oncol 7:347-353, 1996
4. Desai SP, Zalupski MM: Optimum cytotoxic therapy for advanced pancreatic cancer, in Lowy AM, Leach SD, Philip PA (eds): Pancreatic Cancer. New York, NY, Springer, 2008 pp 511-534
5. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007
6. Smit VT, Boot AJ, Smits AM, et al: KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 25:7773-7782, 1998
7. Almoguera C, Shibata D, Forrester K, et al: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554, 1988
8. Caldas C, Hahn SA, Hruban RH, et al: Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 54:3568-3573, 1994
9. Yanagisawa A, Ohtake K, Ohashi K, et al: Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 53:953-956, 1993
10. Cerny WL, Mangold KA, Scarpelli DG: K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 52:4507-4513, 1992
11. Hingorani SR, Petricoin EF, Maitra A, et al: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437-450, 2003
12. Aguirre AJ, Bardeesy N, Sinha M, et al: Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112-3126, 2003
13. Zhu K, Hamilton AD, Sebti SM: Farnesyltransferase inhibitors as anticancer agents: Current status. Curr Opin Investig Drugs 4:1428-1435, 2003
14. Cox AD, Der CJ: Ras family signaling: Therapeutic targeting. Cancer Biol Ther 1:599-606, 2002
15. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430-1438, 2004
16. Rowinsky EK: Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J Clin Oncol 24:2981-2984, 2006
17. Tang Y, Yu J, Field J: Signals from the Ras, Rac, and Rho GTPases converge on the Pak protein kinase in Rat-1 fibroblasts. Mol Cell Biol 19:1881-1891, 1999
18. Kanda A, Kawai H, Suto S, et al: Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 24:7266-7272, 2005
19. Lerner EC, Zhang TT, Knowles DB, et al: Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15:1283-1288, 1997
20. Sun J, Qian Y, Hamilton AD, et al: Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473, 1998
21. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768, 2008
22. Li C, Heidt DG, Dalerba P, et al: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007
23. Simeone DM: Pancreatic cancer stem cells: Implications for the treatment of pancreatic cancer. Clin Cancer Res 14:5646-5648, 2008
24. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313-323, 2007
25. Cruickshank AH: Solid carcinomas of the exocrine pancreas. In: Pathology of the pancreas. London, United Kingdom, Springer-Verlag, 1986, pp 155-177
26. Jackson L, Evers BM: Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat Res 130:39-65, 2006
27. Korc M: Pancreatic cancer-associated stroma production. Am J Surg 194:S84-S86, 2007 (suppl)
28. Farrow B, Sugiyama Y, Chen A, et al: Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 239:763-769, 2004
29. Hwang RF, Moore T, Arumugam T, et al: Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68:918-926, 2008
30. Vonlaufen A, Joshi S, Qu C, et al: Pancreatic stellate cells: Partners in crime with pancreatic cancer cells. Cancer Res 68:2085-2093, 2008
31. Ide T, Kitajima Y, Miyoshi A, et al: Tumorstromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int J Cancer 119:2750-2759, 2006
32. Lee CJ, Li C, Simeone DM: Human pancreatic cancer stem cells: Implications for how we treat pancreatic cancer. Transl Oncol 1:14-18, 2008
33. Kindler HL, Niedzwiecki D, Hollis D, et al: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: A preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25: 199s, 2007 (abstr 4508)
34. Mahadevan D, Von Hoff DD: Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6:1186-1197, 2007
35. Hezel AF, Kimmelman AC, Stanger BZ, et al: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20:1218-1249, 2006
36. Gutierrez-Barrera AM, Menter DG, Abbruzzese JL, et al: Establishment of three-dimensional cultures of human pancreatic duct epithelial cells. Biochem Biophys Res Commun 358:698-703, 2007
37. Azmi AS, Mohammad M, Kaseb AO, et al: Utility of animal models in pancreatic cancer research, in Lowy AM, Leach SD, Philip PA (eds): Pancreatic Cancer, New York, NY. Springer, 2008, pp 577-599
38. Hruban RH, Adsay NV, Albores-Saavedra J, et al: Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations. Cancer Res 66:95-106, 2006
39. Rubio-Viqueira B, Jimeno A, Cusatis G, et al: An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652-4661, 2006
40. Rijken AM, Hu J, Perlman EJ, et al: Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer 26:185-191, 1999
41. Philip PA, Benedetti J, Fenoglio-Preiser C, et al: Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic adenocarcinoma: SWOG S0205 study. J Clin Oncol 25:199s, 2007 (abstr LBA4509)
42. Taylor JMG, Braun TM, Li Z: Comparing an experimental agent to a standard agent; relative merits of a one-arm or randomized two-arm phase II design. Clin Trials 3:335-348, 2006
43. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
44. Korn EL, Liu P-Y, Lee SJ, et al: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527-534, 2008
45. Lowy AM: Neoadjuvant therapy for pancreas cancer. J Gastrointest Surg 12:1600-1608, 2008
46. Katz MH, Evans DB, Sun CC, et al: Borderline resectable pancreatic cancer: The importance of the emerging stage of disease. J Am Coll Surg 206:833-846, 2008
47. Rosenberg L, Lipsett M: Biotherapeutic approaches to pancreatic cancer. Expert Opin Biol Ther 3:319-337, 2003
48. Korman A, Yellin M, Keler T, et al: Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 6:582-591, 2005
49. Kuriyama H, Watanabe S, Kjaergaard J, et al: Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol 243:30-40, 2006
50. Fong L, Small EJ: Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26:5275-5283, 2008
51. Plate JM, Plate AE, Shott S, et al: Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915-925, 2005
52. Jaffee EM, Hruban RH, Biedrzycki B, et al: Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 19:145-156, 2001
53. Laheru D, Biedrzycki B, Thomas AM, et al: Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods Mol Med 103:299-327, 2005
54. Emens LA: Chemotherapy and tumor immunity: An unexpected collaboration. Front Biosci 13: 249-257, 2008
55. Kurihara T, Itoi T, Sofuni A, et al: Detection of circulating tumor cells in patients with pancreatic cancer: A preliminary result. J Hepatobiliary Pancreat Surg 15:189-195, 2008
56. Berger AC, Garcia M, Hoffman J, et al: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 26:5918-5922, 2008
57. Burk U, Schubert J, Wellner U, et al: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582-589, 2008
58. Yang J, Mani S, Donaher J, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927-939, 2004
59. Buck E, Eyzaguirre A, Barr S, et al: Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6:532-541, 2007
60. Thomson S, Buck E, Petti F, et al: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65:9455-9462, 2005
61. Shah AN, Summy JM, Zhang J, et al: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14:3629-3637, 2007